Story perspectives

Vitruvias Recalls Superpotent USP 30mg Thyroid Tablets Nationwide

8/25/2026

Summary

Story summary

Vitruvias Therapeutics is voluntarily recalling one lot of Thyroid Tablets, USP 30 mg.
The recalled lot is 504950 (NDC 69680-166-00) expiring September 30, 2026, distributed nationwide Jan 31–Sep 30, 2025.
Testing showed the tablets could be superpotent, risking hyperthyroidism and symptoms like weight loss and rapid heart rate.
Elderly, pregnant women, and infants face higher risk from the superpotent thyroid tablets.
Vitruvias asks wholesalers to stop distribution, destroy the product, and contact 256-239-9373 or safety@vitruvias.com.

1 of 1

Story summary

Vitruvias Therapeutics is voluntarily recalling one lot of Thyroid Tablets, USP 30 mg.
The recalled lot is 504950 (NDC 69680-166-00) expiring September 30, 2026, distributed nationwide Jan 31–Sep 30, 2025.
Testing showed the tablets could be superpotent, risking hyperthyroidism and symptoms like weight loss and rapid heart rate.
Elderly, pregnant women, and infants face higher risk from the superpotent thyroid tablets.
Vitruvias asks wholesalers to stop distribution, destroy the product, and contact 256-239-9373 or safety@vitruvias.com.